ReviewCritical reviews in oncology/hematology2013
Biomolecular markers of cancer-associated thromboembolism.
Review in Critical reviews in oncology/hematology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Prognostic value of D-dimer in treatment and follow up for patients who underwent radiotherapy in advanced lung cancer.PloS one · 2025Observational
- Emerging Biomarkers for Assessing Thrombotic Risk in Patients Receiving Direct Oral Anticoagulants (DOACs).Cardiovascular & hematological agents in medicinal chemistry · 2025Review
- The clinical association between coagulation indexes, platelet-related parameters, and bone metastasis of newly diagnosed prostate cancer.European journal of medical research · 2023Article
- D-dimer, Fibrinogen and Tumor Marker Levels in Patients with benign and Malignant Ovarian Tumors.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Predicting venous thromboembolism (VTE) risk in cancer patients using machine learning.Health care science · 2023Article
- Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study.Journal of thoracic disease · 2022Article
- Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple Myeloma.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Soluble P-selectin and correlation with Prothrombin Fragment 1 + 2 in myeloid malignancies in Cipto Mangunkusumo general hospital.Thrombosis journal · 2021Article
- D-Dimer: A Potential Solution to Problems of Cancer Screening, Surveillance, and Prognosis Assessment.Cureus · 2021Review
- Inflammatory Biomarkers in the Short-Term Prognosis of Venous Thromboembolism: A Narrative Review.International journal of molecular sciences · 2021Review
- Systemic Coagulation Markers Especially Fibrinogen Are Closely Associated with the Aggressiveness of Prostate Cancer in Patients Who Underwent Transrectal Ultrasound-Guided Prostate Biopsy.Disease markers · 2021Article
- Application of an elevated plasma D-dimer cut-off value improves prognosis prediction of advanced non-small cell lung cancer.Annals of translational medicine · 2020Article
- Role of P-selectin in thromboembolic events in patients with cancer.Molecular and clinical oncology · 2018Article
- Fibrinogen and D-dimer levels in prostate cancer: Preliminary results.Prostate international · 2017Article
- Coagulation Biomarkers in Healthy Chinese-Origin Rhesus Macaques (Macaca mulatta).Journal of the American Association for Laboratory Animal Science : JAALAS · 2016Article
- Cancer and Thrombosis: The Platelet Perspective.Frontiers in cell and developmental biology · 2016Review
- Venous thrombosis and cancer: from mouse models to clinical trials.Journal of thrombosis and haemostasis : JTH · 2015Review
- The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear.Thrombosis research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Venous thromboembolism (VTE; deep venous thrombosis and pulmonary embolism) is associated with a poor prognosis in most malignancies and is a major cause of death among cancer patients. Universal anticoagulation for primary thromboprophylaxis in the outpatient setting is precluded by potential bleeding complications, especially without sufficient evidence that all patients would benefit from such prophylaxis. Therefore, appropriately targeting cancer patients for thromboprophylaxis is key to reducing morbidity and perhaps mortality. Predictive biomarkers could aid in identifying patients at high risk for VTE. Possible biomarkers for VTE include C-reactive protein, platelet and leukocyte counts, D-dimer and prothrombin fragment 1+2, procoagulant factor VIII, tissue factor, and soluble P-selectin. Evidence is emerging to support the use of risk assessment models in selecting appropriate candidates for primary thromboprophylaxis in the cancer setting. Further studies are needed to optimize these models and determine utility in reducing morbidity and mortality from cancer-associated thromboembolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.